GlassScriptPhysician profile
Erin B Jungbauer
NPI 1972546927
$2,658.49
in general payments reported to CMS, 2019-2025
37 companies · $188 in 2025
The $188 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $588 · 2020: $276 · 2021: $461 · 2022: $589 · 2023: $331 · 2024: $224 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $743.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $488.21 | 2020-2025 | |
| Pfizer INC. | $383.37 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $236.49 | 2019-2021 | |
| Amgen INC. | $196.32 | 2019-2024 | Repatha, Otezla |
| Novo Nordisk INC | $144.67 | 2020-2023 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $127.92 | 2019-2024 | Spravato |
| Astellas Pharma US INC | $103.82 | 2020-2024 | Veozah |
| Lilly USA, LLC | $86.30 | 2020-2023 | Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $85.74 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $58.43 | 2022-2023 | Livalo, Seglentis |
| Bayer Healthcare Pharmaceuticals INC. | $53.84 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.10 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.34 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $47.93 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.99 | 2019-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.49 | 2022-2025 | Caplyta |
| Jazz Pharmaceuticals INC. | $38.71 | 2020-2021 | |
| Corium, LLC | $38.37 | 2022-2025 | Azstarys |
| Sunovion Pharmaceuticals INC. | $37.24 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $36.74 | 2021 | |
| Mylan Specialty L.P. | $33.06 | 2019-2020 | |
| Amarin Pharma, INC. | $28.22 | 2020-2021 | |
| Organon LLC | $26.40 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $23.25 | 2019 | |
| Inspire Medical Systems, INC. | $22.87 | 2025 | Inspire |
| Supernus Pharmaceuticals, INC. | $22.47 | 2021 | |
| Neurocrine Biosciences, INC. | $16.75 | 2025 | |
| Avanir Pharmaceuticals, INC. | $16.52 | 2019 | |
| Exact Sciences Corporation | $15.90 | 2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $15.85 | 2019 | |
| Dexcom, INC. | $14.00 | 2021 | |
| Ironshore Pharmaceuticals INC. | $13.46 | 2019 | |
| Antares Pharma, INC. | $13.08 | 2022 | |
| Xeris Pharmaceuticals, INC. | $13.05 | 2022 | |
| Esperion Therapeutics, INC. | $12.72 | 2022 | |
| Arbor Pharmaceuticals, INC. | $11.79 | 2019 | |
| Dermira, INC. | $11.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Jungbauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.